nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—PTGIS—gall bladder—Crohn's disease	0.0377	0.273	CbGeAlD
Epoprostenol—PTGIS—smooth muscle tissue—Crohn's disease	0.0188	0.136	CbGeAlD
Epoprostenol—P2RY12—epithelium—Crohn's disease	0.0175	0.127	CbGeAlD
Epoprostenol—PTGIS—mammalian vulva—Crohn's disease	0.0169	0.123	CbGeAlD
Epoprostenol—Dinoprostone—PTGER4—Crohn's disease	0.0151	1	CrCbGaD
Epoprostenol—PTGIR—epithelium—Crohn's disease	0.0112	0.0812	CbGeAlD
Epoprostenol—PTGIR—smooth muscle tissue—Crohn's disease	0.0108	0.0783	CbGeAlD
Epoprostenol—PTGIR—digestive system—Crohn's disease	0.00851	0.0618	CbGeAlD
Epoprostenol—PTGIS—lymph node—Crohn's disease	0.00847	0.0615	CbGeAlD
Epoprostenol—Platelet count decreased—Mesalazine—Crohn's disease	0.00704	0.0194	CcSEcCtD
Epoprostenol—Enlargement abdomen—Mesalazine—Crohn's disease	0.00696	0.0192	CcSEcCtD
Epoprostenol—Sepsis—Mercaptopurine—Crohn's disease	0.00669	0.0185	CcSEcCtD
Epoprostenol—Hyperthyroidism—Prednisone—Crohn's disease	0.0056	0.0154	CcSEcCtD
Epoprostenol—Pleural effusion—Mesalazine—Crohn's disease	0.00547	0.0151	CcSEcCtD
Epoprostenol—Hyperaesthesia—Mesalazine—Crohn's disease	0.00533	0.0147	CcSEcCtD
Epoprostenol—PTGIR—lymph node—Crohn's disease	0.00486	0.0353	CbGeAlD
Epoprostenol—Vasodilation—Mesalazine—Crohn's disease	0.00477	0.0131	CcSEcCtD
Epoprostenol—Vasodilation procedure—Mesalazine—Crohn's disease	0.00477	0.0131	CcSEcCtD
Epoprostenol—Rectal haemorrhage—Mesalazine—Crohn's disease	0.00464	0.0128	CcSEcCtD
Epoprostenol—Pancytopenia—Mercaptopurine—Crohn's disease	0.0046	0.0127	CcSEcCtD
Epoprostenol—Neck pain—Mesalazine—Crohn's disease	0.00424	0.0117	CcSEcCtD
Epoprostenol—Musculoskeletal pain—Mesalazine—Crohn's disease	0.00424	0.0117	CcSEcCtD
Epoprostenol—Influenza like illness—Mesalazine—Crohn's disease	0.00407	0.0112	CcSEcCtD
Epoprostenol—Cramps of lower extremities—Mesalazine—Crohn's disease	0.00385	0.0106	CcSEcCtD
Epoprostenol—Hepatic failure—Azathioprine—Crohn's disease	0.00371	0.0102	CcSEcCtD
Epoprostenol—Eczema—Mesalazine—Crohn's disease	0.00338	0.00932	CcSEcCtD
Epoprostenol—Hepatic failure—Mesalazine—Crohn's disease	0.00338	0.00932	CcSEcCtD
Epoprostenol—Thirst—Mesalazine—Crohn's disease	0.00319	0.0088	CcSEcCtD
Epoprostenol—Arthritis—Mesalazine—Crohn's disease	0.00313	0.00862	CcSEcCtD
Epoprostenol—Anaemia—Mercaptopurine—Crohn's disease	0.00312	0.00859	CcSEcCtD
Epoprostenol—CYP2C9—digestive system—Crohn's disease	0.00304	0.0221	CbGeAlD
Epoprostenol—Arthralgia—Mercaptopurine—Crohn's disease	0.00287	0.00791	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.00285	0.00786	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Mesalazine—Crohn's disease	0.00278	0.00765	CcSEcCtD
Epoprostenol—Abdominal discomfort—Azathioprine—Crohn's disease	0.00276	0.00762	CcSEcCtD
Epoprostenol—Oedema—Mercaptopurine—Crohn's disease	0.00275	0.00759	CcSEcCtD
Epoprostenol—Pancytopenia—Azathioprine—Crohn's disease	0.00274	0.00755	CcSEcCtD
Epoprostenol—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.00269	0.00743	CcSEcCtD
Epoprostenol—Gastritis—Mesalazine—Crohn's disease	0.00269	0.00742	CcSEcCtD
Epoprostenol—Skin disorder—Mercaptopurine—Crohn's disease	0.00267	0.00737	CcSEcCtD
Epoprostenol—Endocrine disorder—Prednisone—Crohn's disease	0.00267	0.00737	CcSEcCtD
Epoprostenol—Abdominal distension—Mesalazine—Crohn's disease	0.00264	0.00729	CcSEcCtD
Epoprostenol—Anorexia—Mercaptopurine—Crohn's disease	0.00262	0.00723	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.00262	0.0054	CbGpPWpGaD
Epoprostenol—Pneumonia—Azathioprine—Crohn's disease	0.00259	0.00713	CcSEcCtD
Epoprostenol—Infestation NOS—Azathioprine—Crohn's disease	0.00257	0.00709	CcSEcCtD
Epoprostenol—Infestation—Azathioprine—Crohn's disease	0.00257	0.00709	CcSEcCtD
Epoprostenol—PTGER1—GPCR ligand binding—MLN—Crohn's disease	0.00257	0.00531	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—MLN—Crohn's disease	0.00257	0.00531	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00254	0.00525	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.00254	0.00524	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.00254	0.00524	CbGpPWpGaD
Epoprostenol—Abdominal discomfort—Mesalazine—Crohn's disease	0.00252	0.00694	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.00251	0.00691	CcSEcCtD
Epoprostenol—Pancytopenia—Mesalazine—Crohn's disease	0.00249	0.00688	CcSEcCtD
Epoprostenol—PTGIS—Adipogenesis—SMAD3—Crohn's disease	0.00243	0.00501	CbGpPWpGaD
Epoprostenol—Decreased appetite—Mercaptopurine—Crohn's disease	0.00239	0.0066	CcSEcCtD
Epoprostenol—Weight decreased—Mesalazine—Crohn's disease	0.00238	0.00655	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00238	0.00655	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.00236	0.00488	CbGpPWpGaD
Epoprostenol—Pneumonia—Mesalazine—Crohn's disease	0.00236	0.00649	CcSEcCtD
Epoprostenol—Infestation—Mesalazine—Crohn's disease	0.00234	0.00646	CcSEcCtD
Epoprostenol—Infestation NOS—Mesalazine—Crohn's disease	0.00234	0.00646	CcSEcCtD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00234	0.00483	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00234	0.00483	CbGpPWpGaD
Epoprostenol—Depression—Mesalazine—Crohn's disease	0.00234	0.00644	CcSEcCtD
Epoprostenol—Haemoglobin—Azathioprine—Crohn's disease	0.00232	0.0064	CcSEcCtD
Epoprostenol—Haemorrhage—Azathioprine—Crohn's disease	0.00231	0.00636	CcSEcCtD
Epoprostenol—Urinary tract infection—Mesalazine—Crohn's disease	0.00228	0.00628	CcSEcCtD
Epoprostenol—Sweating—Mesalazine—Crohn's disease	0.00225	0.00619	CcSEcCtD
Epoprostenol—Haematuria—Mesalazine—Crohn's disease	0.00223	0.00616	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.00222	0.00459	CbGpPWpGaD
Epoprostenol—Epistaxis—Mesalazine—Crohn's disease	0.00221	0.00609	CcSEcCtD
Epoprostenol—Sinusitis—Mesalazine—Crohn's disease	0.0022	0.00606	CcSEcCtD
Epoprostenol—Body temperature increased—Mercaptopurine—Crohn's disease	0.00218	0.006	CcSEcCtD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.00218	0.00449	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.00218	0.00449	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—CCR6—Crohn's disease	0.00212	0.00437	CbGpPWpGaD
Epoprostenol—Haemoglobin—Mesalazine—Crohn's disease	0.00211	0.00583	CcSEcCtD
Epoprostenol—Rhinitis—Mesalazine—Crohn's disease	0.00211	0.00581	CcSEcCtD
Epoprostenol—Haemorrhage—Mesalazine—Crohn's disease	0.0021	0.0058	CcSEcCtD
Epoprostenol—Pharyngitis—Mesalazine—Crohn's disease	0.00209	0.00575	CcSEcCtD
Epoprostenol—Mediastinal disorder—Azathioprine—Crohn's disease	0.00208	0.00573	CcSEcCtD
Epoprostenol—Oedema peripheral—Mesalazine—Crohn's disease	0.00207	0.00571	CcSEcCtD
Epoprostenol—Chills—Azathioprine—Crohn's disease	0.00207	0.00571	CcSEcCtD
Epoprostenol—Connective tissue disorder—Mesalazine—Crohn's disease	0.00207	0.0057	CcSEcCtD
Epoprostenol—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00203	0.00559	CcSEcCtD
Epoprostenol—Pulmonary oedema—Prednisone—Crohn's disease	0.00197	0.00544	CcSEcCtD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.00197	0.00406	CbGpPWpGaD
Epoprostenol—PTGIS—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—Crohn's disease	0.00196	0.00404	CbGpPWpGaD
Epoprostenol—Cardiac disorder—Mesalazine—Crohn's disease	0.00195	0.00538	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—CCR9—Crohn's disease	0.00194	0.004	CbGpPWpGaD
Epoprostenol—Hyperkinesia—Prednisone—Crohn's disease	0.00193	0.00533	CcSEcCtD
Epoprostenol—Sepsis—Prednisone—Crohn's disease	0.00192	0.0053	CcSEcCtD
Epoprostenol—Angiopathy—Mesalazine—Crohn's disease	0.00191	0.00526	CcSEcCtD
Epoprostenol—Mediastinal disorder—Mesalazine—Crohn's disease	0.00189	0.00522	CcSEcCtD
Epoprostenol—Chills—Mesalazine—Crohn's disease	0.00189	0.0052	CcSEcCtD
Epoprostenol—Diarrhoea—Mercaptopurine—Crohn's disease	0.00188	0.00519	CcSEcCtD
Epoprostenol—Anaemia—Azathioprine—Crohn's disease	0.00186	0.00512	CcSEcCtD
Epoprostenol—Mental disorder—Mesalazine—Crohn's disease	0.00184	0.00508	CcSEcCtD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—GPX4—Crohn's disease	0.00183	0.00379	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.00181	0.00373	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.00181	0.00373	CbGpPWpGaD
Epoprostenol—Flatulence—Mesalazine—Crohn's disease	0.0018	0.00497	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—GPR65—Crohn's disease	0.0018	0.00372	CbGpPWpGaD
Epoprostenol—Tension—Mesalazine—Crohn's disease	0.0018	0.00495	CcSEcCtD
Epoprostenol—PTGER1—GPCR ligand binding—CCR9—Crohn's disease	0.00178	0.00368	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CCR9—Crohn's disease	0.00178	0.00368	CbGpPWpGaD
Epoprostenol—Nervousness—Mesalazine—Crohn's disease	0.00178	0.0049	CcSEcCtD
Epoprostenol—Back pain—Mesalazine—Crohn's disease	0.00177	0.00488	CcSEcCtD
Epoprostenol—Muscle spasms—Mesalazine—Crohn's disease	0.00176	0.00485	CcSEcCtD
Epoprostenol—Vomiting—Mercaptopurine—Crohn's disease	0.00175	0.00482	CcSEcCtD
Epoprostenol—Rash—Mercaptopurine—Crohn's disease	0.00174	0.00478	CcSEcCtD
Epoprostenol—Dermatitis—Mercaptopurine—Crohn's disease	0.00173	0.00478	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.00173	0.00358	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.00173	0.00357	CbGpPWpGaD
Epoprostenol—Tremor—Mesalazine—Crohn's disease	0.00171	0.00473	CcSEcCtD
Epoprostenol—Myalgia—Azathioprine—Crohn's disease	0.00171	0.00472	CcSEcCtD
Epoprostenol—Arthralgia—Azathioprine—Crohn's disease	0.00171	0.00472	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.0017	0.00468	CcSEcCtD
Epoprostenol—PTGER1—G alpha (q) signalling events—RASGRP1—Crohn's disease	0.0017	0.0035	CbGpPWpGaD
Epoprostenol—Anaemia—Mesalazine—Crohn's disease	0.00169	0.00466	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.00168	0.00348	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—IL3—Crohn's disease	0.00167	0.00344	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—GPR65—Crohn's disease	0.00166	0.00342	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—GPR65—Crohn's disease	0.00166	0.00342	CbGpPWpGaD
Epoprostenol—Cardiac failure—Prednisone—Crohn's disease	0.00165	0.00454	CcSEcCtD
Epoprostenol—Syncope—Mesalazine—Crohn's disease	0.00164	0.00452	CcSEcCtD
Epoprostenol—Nausea—Mercaptopurine—Crohn's disease	0.00163	0.00451	CcSEcCtD
Epoprostenol—Infection—Azathioprine—Crohn's disease	0.00163	0.00449	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.00162	0.00335	CbGpPWpGaD
Epoprostenol—Palpitations—Mesalazine—Crohn's disease	0.00162	0.00446	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—RASGRP1—Crohn's disease	0.00161	0.00333	CbGpPWpGaD
Epoprostenol—Loss of consciousness—Mesalazine—Crohn's disease	0.00161	0.00443	CcSEcCtD
Epoprostenol—Thrombocytopenia—Azathioprine—Crohn's disease	0.00161	0.00443	CcSEcCtD
Epoprostenol—Cough—Mesalazine—Crohn's disease	0.0016	0.0044	CcSEcCtD
Epoprostenol—Skin disorder—Azathioprine—Crohn's disease	0.00159	0.00439	CcSEcCtD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.00159	0.00329	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.00159	0.00329	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—MLN—Crohn's disease	0.00158	0.00326	CbGpPWpGaD
Epoprostenol—Arthralgia—Mesalazine—Crohn's disease	0.00156	0.0043	CcSEcCtD
Epoprostenol—Chest pain—Mesalazine—Crohn's disease	0.00156	0.0043	CcSEcCtD
Epoprostenol—Myalgia—Mesalazine—Crohn's disease	0.00156	0.0043	CcSEcCtD
Epoprostenol—Anxiety—Mesalazine—Crohn's disease	0.00155	0.00428	CcSEcCtD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.00155	0.0032	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.00155	0.0032	CbGpPWpGaD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.00155	0.00427	CcSEcCtD
Epoprostenol—Hypotension—Azathioprine—Crohn's disease	0.00153	0.00422	CcSEcCtD
Epoprostenol—Dry mouth—Mesalazine—Crohn's disease	0.00152	0.0042	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—Crohn's disease	0.00152	0.00313	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—ACKR2—Crohn's disease	0.00151	0.00312	CbGpPWpGaD
Epoprostenol—Confusional state—Mesalazine—Crohn's disease	0.00151	0.00415	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.00149	0.00412	CcSEcCtD
Epoprostenol—Oedema—Mesalazine—Crohn's disease	0.00149	0.00412	CcSEcCtD
Epoprostenol—Anaphylactic shock—Mesalazine—Crohn's disease	0.00149	0.00412	CcSEcCtD
Epoprostenol—Infection—Mesalazine—Crohn's disease	0.00148	0.00409	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.00148	0.00306	CbGpPWpGaD
Epoprostenol—Shock—Mesalazine—Crohn's disease	0.00147	0.00405	CcSEcCtD
Epoprostenol—Nervous system disorder—Mesalazine—Crohn's disease	0.00146	0.00404	CcSEcCtD
Epoprostenol—Thrombocytopenia—Mesalazine—Crohn's disease	0.00146	0.00403	CcSEcCtD
Epoprostenol—Tachycardia—Mesalazine—Crohn's disease	0.00146	0.00402	CcSEcCtD
Epoprostenol—PTGER1—GPCR downstream signaling—MLN—Crohn's disease	0.00145	0.003	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—MLN—Crohn's disease	0.00145	0.003	CbGpPWpGaD
Epoprostenol—Skin disorder—Mesalazine—Crohn's disease	0.00145	0.004	CcSEcCtD
Epoprostenol—Hyperhidrosis—Mesalazine—Crohn's disease	0.00144	0.00398	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—F5—Crohn's disease	0.00143	0.00296	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—MLN—Crohn's disease	0.00143	0.00296	CbGpPWpGaD
Epoprostenol—Anorexia—Mesalazine—Crohn's disease	0.00142	0.00393	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.00142	0.0039	CcSEcCtD
Epoprostenol—Abdominal distension—Prednisone—Crohn's disease	0.0014	0.00386	CcSEcCtD
Epoprostenol—Hypotension—Mesalazine—Crohn's disease	0.0014	0.00385	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—ACKR2—Crohn's disease	0.00139	0.00287	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—ACKR2—Crohn's disease	0.00139	0.00287	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.00136	0.00282	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.00136	0.00282	CbGpPWpGaD
Epoprostenol—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.00136	0.00375	CcSEcCtD
Epoprostenol—Insomnia—Mesalazine—Crohn's disease	0.00135	0.00372	CcSEcCtD
Epoprostenol—Paraesthesia—Mesalazine—Crohn's disease	0.00134	0.0037	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Azathioprine—Crohn's disease	0.00134	0.0037	CcSEcCtD
Epoprostenol—Dyspnoea—Mesalazine—Crohn's disease	0.00133	0.00367	CcSEcCtD
Epoprostenol—Somnolence—Mesalazine—Crohn's disease	0.00133	0.00366	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—F5—Crohn's disease	0.00132	0.00273	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—MLN—Crohn's disease	0.00132	0.00272	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—MLN—Crohn's disease	0.00132	0.00272	CbGpPWpGaD
Epoprostenol—Dyspepsia—Mesalazine—Crohn's disease	0.00131	0.00362	CcSEcCtD
Epoprostenol—Decreased appetite—Mesalazine—Crohn's disease	0.0013	0.00358	CcSEcCtD
Epoprostenol—Body temperature increased—Azathioprine—Crohn's disease	0.0013	0.00357	CcSEcCtD
Epoprostenol—Abdominal pain—Azathioprine—Crohn's disease	0.0013	0.00357	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.00129	0.00356	CcSEcCtD
Epoprostenol—Fatigue—Mesalazine—Crohn's disease	0.00129	0.00355	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—CCR6—Crohn's disease	0.00128	0.00265	CbGpPWpGaD
Epoprostenol—Pain—Mesalazine—Crohn's disease	0.00128	0.00352	CcSEcCtD
Epoprostenol—Constipation—Mesalazine—Crohn's disease	0.00128	0.00352	CcSEcCtD
Epoprostenol—Weight decreased—Prednisone—Crohn's disease	0.00126	0.00347	CcSEcCtD
Epoprostenol—Depression—Prednisone—Crohn's disease	0.00124	0.00341	CcSEcCtD
Epoprostenol—Acute coronary syndrome—Prednisone—Crohn's disease	0.00122	0.00337	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Mesalazine—Crohn's disease	0.00122	0.00337	CcSEcCtD
Epoprostenol—PTGIS—Disease—RSPO3—Crohn's disease	0.00122	0.00251	CbGpPWpGaD
Epoprostenol—Myocardial infarction—Prednisone—Crohn's disease	0.00121	0.00335	CcSEcCtD
Epoprostenol—Hypersensitivity—Azathioprine—Crohn's disease	0.00121	0.00333	CcSEcCtD
Epoprostenol—Urticaria—Mesalazine—Crohn's disease	0.00119	0.00327	CcSEcCtD
Epoprostenol—Body temperature increased—Mesalazine—Crohn's disease	0.00118	0.00326	CcSEcCtD
Epoprostenol—Abdominal pain—Mesalazine—Crohn's disease	0.00118	0.00326	CcSEcCtD
Epoprostenol—PTGER1—GPCR ligand binding—CCR6—Crohn's disease	0.00118	0.00244	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CCR6—Crohn's disease	0.00118	0.00244	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—IL2RA—Crohn's disease	0.00117	0.00241	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PLA2G4F—Crohn's disease	0.00116	0.0024	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—SEL1L—Crohn's disease	0.00115	0.00238	CbGpPWpGaD
Epoprostenol—Bradycardia—Prednisone—Crohn's disease	0.00113	0.00312	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—PTGER4—Crohn's disease	0.00113	0.00233	CbGpPWpGaD
Epoprostenol—Diarrhoea—Azathioprine—Crohn's disease	0.00112	0.00309	CcSEcCtD
Epoprostenol—Haemoglobin—Prednisone—Crohn's disease	0.00112	0.00308	CcSEcCtD
Epoprostenol—Haemorrhage—Prednisone—Crohn's disease	0.00111	0.00307	CcSEcCtD
Epoprostenol—PTGIS—Adipogenesis—STAT3—Crohn's disease	0.00111	0.00229	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Mesalazine—Crohn's disease	0.0011	0.00303	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—CCR9—Crohn's disease	0.00109	0.00226	CbGpPWpGaD
Epoprostenol—Connective tissue disorder—Prednisone—Crohn's disease	0.00109	0.00301	CcSEcCtD
Epoprostenol—Dizziness—Azathioprine—Crohn's disease	0.00108	0.00299	CcSEcCtD
Epoprostenol—Asthenia—Mesalazine—Crohn's disease	0.00107	0.00295	CcSEcCtD
Epoprostenol—Pruritus—Mesalazine—Crohn's disease	0.00106	0.00291	CcSEcCtD
Epoprostenol—Vomiting—Azathioprine—Crohn's disease	0.00104	0.00287	CcSEcCtD
Epoprostenol—PTGIR—GPCR ligand binding—PTGER4—Crohn's disease	0.00104	0.00215	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—PTGER4—Crohn's disease	0.00104	0.00215	CbGpPWpGaD
Epoprostenol—Rash—Azathioprine—Crohn's disease	0.00103	0.00285	CcSEcCtD
Epoprostenol—PTGIS—Disease—LTF—Crohn's disease	0.00103	0.00213	CbGpPWpGaD
Epoprostenol—Dermatitis—Azathioprine—Crohn's disease	0.00103	0.00285	CcSEcCtD
Epoprostenol—Flushing—Prednisone—Crohn's disease	0.00103	0.00285	CcSEcCtD
Epoprostenol—Headache—Azathioprine—Crohn's disease	0.00103	0.00283	CcSEcCtD
Epoprostenol—Diarrhoea—Mesalazine—Crohn's disease	0.00102	0.00282	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—GPR65—Crohn's disease	0.00102	0.0021	CbGpPWpGaD
Epoprostenol—Angiopathy—Prednisone—Crohn's disease	0.00101	0.00278	CcSEcCtD
Epoprostenol—PTGIR—GPCR downstream signaling—CCR9—Crohn's disease	0.00101	0.00208	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CCR9—Crohn's disease	0.00101	0.00208	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CCR9—Crohn's disease	0.000994	0.00205	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—MTMR3—Crohn's disease	0.00099	0.00204	CbGpPWpGaD
Epoprostenol—Dizziness—Mesalazine—Crohn's disease	0.000988	0.00272	CcSEcCtD
Epoprostenol—Mental disorder—Prednisone—Crohn's disease	0.000975	0.00269	CcSEcCtD
Epoprostenol—Nausea—Azathioprine—Crohn's disease	0.000974	0.00269	CcSEcCtD
Epoprostenol—PTGIS—Adipogenesis—TNF—Crohn's disease	0.000959	0.00198	CbGpPWpGaD
Epoprostenol—Vomiting—Mesalazine—Crohn's disease	0.00095	0.00262	CcSEcCtD
Epoprostenol—Rash—Mesalazine—Crohn's disease	0.000942	0.0026	CcSEcCtD
Epoprostenol—Dermatitis—Mesalazine—Crohn's disease	0.000941	0.00259	CcSEcCtD
Epoprostenol—PTGER1—GPCR downstream signaling—GPR65—Crohn's disease	0.000936	0.00193	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—GPR65—Crohn's disease	0.000936	0.00193	CbGpPWpGaD
Epoprostenol—Headache—Mesalazine—Crohn's disease	0.000936	0.00258	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—GPR65—Crohn's disease	0.000924	0.00191	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CCR9—Crohn's disease	0.000914	0.00189	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCR9—Crohn's disease	0.000914	0.00189	CbGpPWpGaD
Epoprostenol—Anaemia—Prednisone—Crohn's disease	0.000895	0.00247	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—ACKR2—Crohn's disease	0.000893	0.00184	CbGpPWpGaD
Epoprostenol—Agitation—Prednisone—Crohn's disease	0.00089	0.00245	CcSEcCtD
Epoprostenol—Nausea—Mesalazine—Crohn's disease	0.000887	0.00245	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—ITGA4—Crohn's disease	0.000882	0.00182	CbGpPWpGaD
Epoprostenol—Syncope—Prednisone—Crohn's disease	0.000868	0.00239	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—IL3—Crohn's disease	0.00086	0.00178	CbGpPWpGaD
Epoprostenol—Loss of consciousness—Prednisone—Crohn's disease	0.000851	0.00235	CcSEcCtD
Epoprostenol—PTGER1—Signaling by GPCR—GPR65—Crohn's disease	0.00085	0.00175	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—GPR65—Crohn's disease	0.00085	0.00175	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MLN—Crohn's disease	0.000847	0.00175	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—ALB—Crohn's disease	0.000845	0.00174	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—GCKR—Crohn's disease	0.000833	0.00172	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—RASGRP1—Crohn's disease	0.000832	0.00172	CbGpPWpGaD
Epoprostenol—Arthralgia—Prednisone—Crohn's disease	0.000824	0.00227	CcSEcCtD
Epoprostenol—Myalgia—Prednisone—Crohn's disease	0.000824	0.00227	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—ACKR2—Crohn's disease	0.000822	0.0017	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ACKR2—Crohn's disease	0.000822	0.0017	CbGpPWpGaD
Epoprostenol—Anxiety—Prednisone—Crohn's disease	0.000822	0.00226	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000819	0.00226	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—ITGA4—Crohn's disease	0.000812	0.00168	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—IL3—Crohn's disease	0.000791	0.00163	CbGpPWpGaD
Epoprostenol—Anaphylactic shock—Prednisone—Crohn's disease	0.00079	0.00218	CcSEcCtD
Epoprostenol—Oedema—Prednisone—Crohn's disease	0.00079	0.00218	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	0.000786	0.00162	CbGpPWpGaD
Epoprostenol—Infection—Prednisone—Crohn's disease	0.000785	0.00216	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—MLN—Crohn's disease	0.000779	0.00161	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MLN—Crohn's disease	0.000779	0.00161	CbGpPWpGaD
Epoprostenol—Shock—Prednisone—Crohn's disease	0.000778	0.00214	CcSEcCtD
Epoprostenol—Nervous system disorder—Prednisone—Crohn's disease	0.000775	0.00214	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	0.000775	0.0016	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TAGAP—Crohn's disease	0.000775	0.0016	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—IL6—Crohn's disease	0.000774	0.0016	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—FADS1—Crohn's disease	0.000771	0.00159	CbGpPWpGaD
Epoprostenol—Tachycardia—Prednisone—Crohn's disease	0.000771	0.00213	CcSEcCtD
Epoprostenol—Skin disorder—Prednisone—Crohn's disease	0.000768	0.00212	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—RASGRP1—Crohn's disease	0.000766	0.00158	CbGpPWpGaD
Epoprostenol—Hyperhidrosis—Prednisone—Crohn's disease	0.000764	0.00211	CcSEcCtD
Epoprostenol—Anorexia—Prednisone—Crohn's disease	0.000753	0.00208	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	0.000739	0.00153	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—SLC11A1—Crohn's disease	0.000736	0.00152	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CCR6—Crohn's disease	0.000725	0.0015	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GPX4—Crohn's disease	0.000722	0.00149	CbGpPWpGaD
Epoprostenol—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.00072	0.00199	CcSEcCtD
Epoprostenol—Insomnia—Prednisone—Crohn's disease	0.000715	0.00197	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—TAGAP—Crohn's disease	0.000713	0.00147	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TAGAP—Crohn's disease	0.000713	0.00147	CbGpPWpGaD
Epoprostenol—Paraesthesia—Prednisone—Crohn's disease	0.00071	0.00196	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—GCKR—Crohn's disease	0.000698	0.00144	CbGpPWpGaD
Epoprostenol—Dyspepsia—Prednisone—Crohn's disease	0.000696	0.00192	CcSEcCtD
Epoprostenol—Decreased appetite—Prednisone—Crohn's disease	0.000687	0.00189	CcSEcCtD
Epoprostenol—P2RY12—G alpha (i) signalling events—CXCL8—Crohn's disease	0.000683	0.00141	CbGpPWpGaD
Epoprostenol—Fatigue—Prednisone—Crohn's disease	0.000681	0.00188	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—RSPO3—Crohn's disease	0.000677	0.0014	CbGpPWpGaD
Epoprostenol—Constipation—Prednisone—Crohn's disease	0.000676	0.00186	CcSEcCtD
Epoprostenol—CYP2C9—Metapathway biotransformation—GPX4—Crohn's disease	0.000673	0.00139	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CCR6—Crohn's disease	0.000667	0.00138	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CCR6—Crohn's disease	0.000667	0.00138	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CCR6—Crohn's disease	0.000658	0.00136	CbGpPWpGaD
Epoprostenol—Gastrointestinal pain—Prednisone—Crohn's disease	0.000646	0.00178	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—SEL1L—Crohn's disease	0.000642	0.00132	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PTGER4—Crohn's disease	0.000638	0.00132	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—RBX1—Crohn's disease	0.000631	0.0013	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HSPA1B—Crohn's disease	0.000631	0.0013	CbGpPWpGaD
Epoprostenol—Urticaria—Prednisone—Crohn's disease	0.000628	0.00173	CcSEcCtD
Epoprostenol—Abdominal pain—Prednisone—Crohn's disease	0.000625	0.00172	CcSEcCtD
Epoprostenol—Body temperature increased—Prednisone—Crohn's disease	0.000625	0.00172	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—RSPO3—Crohn's disease	0.000623	0.00129	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RSPO3—Crohn's disease	0.000623	0.00129	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCR6—Crohn's disease	0.000606	0.00125	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CCR6—Crohn's disease	0.000606	0.00125	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—IL2RA—Crohn's disease	0.000602	0.00124	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SEL1L—Crohn's disease	0.000591	0.00122	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SEL1L—Crohn's disease	0.000591	0.00122	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PTGER4—Crohn's disease	0.000587	0.00121	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PTGER4—Crohn's disease	0.000587	0.00121	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCR9—Crohn's disease	0.000587	0.00121	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Prednisone—Crohn's disease	0.000582	0.00161	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—PTGER4—Crohn's disease	0.000579	0.0012	CbGpPWpGaD
Epoprostenol—Asthenia—Prednisone—Crohn's disease	0.000567	0.00156	CcSEcCtD
Epoprostenol—Pruritus—Prednisone—Crohn's disease	0.000559	0.00154	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—IL2RA—Crohn's disease	0.000554	0.00114	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—UBE2D1—Crohn's disease	0.000554	0.00114	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—GPR65—Crohn's disease	0.000546	0.00113	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—IL3—Crohn's disease	0.000544	0.00112	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000543	0.00112	CbGpPWpGaD
Epoprostenol—Diarrhoea—Prednisone—Crohn's disease	0.000541	0.00149	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—CCR9—Crohn's disease	0.00054	0.00112	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCR9—Crohn's disease	0.00054	0.00112	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PTGER4—Crohn's disease	0.000533	0.0011	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PTGER4—Crohn's disease	0.000533	0.0011	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000526	0.00109	CbGpPWpGaD
Epoprostenol—Dizziness—Prednisone—Crohn's disease	0.000523	0.00144	CcSEcCtD
Epoprostenol—Vomiting—Prednisone—Crohn's disease	0.000503	0.00139	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—GPR65—Crohn's disease	0.000502	0.00104	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GPR65—Crohn's disease	0.000502	0.00104	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—IL3—Crohn's disease	0.0005	0.00103	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—IL3—Crohn's disease	0.0005	0.00103	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000499	0.00103	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000499	0.00103	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	0.000499	0.00103	CbGpPWpGaD
Epoprostenol—Rash—Prednisone—Crohn's disease	0.000498	0.00137	CcSEcCtD
Epoprostenol—Dermatitis—Prednisone—Crohn's disease	0.000498	0.00137	CcSEcCtD
Epoprostenol—Headache—Prednisone—Crohn's disease	0.000495	0.00136	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—IL3—Crohn's disease	0.000494	0.00102	CbGpPWpGaD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—PTGS2—Crohn's disease	0.000493	0.00102	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000484	0.000999	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000484	0.000999	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—RASGRP1—Crohn's disease	0.000477	0.000985	CbGpPWpGaD
Epoprostenol—Nausea—Prednisone—Crohn's disease	0.000469	0.00129	CcSEcCtD
Epoprostenol—PTGER1—Signaling by GPCR—IL3—Crohn's disease	0.000454	0.000938	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL3—Crohn's disease	0.000454	0.000938	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—RASGRP1—Crohn's disease	0.000439	0.000907	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—RASGRP1—Crohn's disease	0.000439	0.000907	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	0.000436	0.0009	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—ALB—Crohn's disease	0.000436	0.000899	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000423	0.000872	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—CXCL8—Crohn's disease	0.000413	0.000853	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—JAK2—Crohn's disease	0.000405	0.000836	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—ALB—Crohn's disease	0.000401	0.000827	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—SMAD3—Crohn's disease	0.000396	0.000818	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCR6—Crohn's disease	0.000389	0.000803	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—IL2RA—Crohn's disease	0.000381	0.000786	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CXCL8—Crohn's disease	0.00038	0.000785	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—CXCL8—Crohn's disease	0.00038	0.000785	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	0.000379	0.000782	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—JAK2—Crohn's disease	0.000373	0.000769	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.000359	0.000742	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCR6—Crohn's disease	0.000358	0.000739	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCR6—Crohn's disease	0.000358	0.000739	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RBX1—Crohn's disease	0.000352	0.000726	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—IL2RA—Crohn's disease	0.00035	0.000723	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—IL2RA—Crohn's disease	0.00035	0.000723	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL2RA—Crohn's disease	0.000346	0.000714	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTGER4—Crohn's disease	0.000342	0.000707	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RBX1—Crohn's disease	0.000324	0.000668	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RBX1—Crohn's disease	0.000324	0.000668	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL2RA—Crohn's disease	0.000318	0.000657	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL2RA—Crohn's disease	0.000318	0.000657	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTGER4—Crohn's disease	0.000315	0.00065	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTGER4—Crohn's disease	0.000315	0.00065	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—UBE2D1—Crohn's disease	0.000308	0.000636	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RIPK2—Crohn's disease	0.000299	0.000617	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL3—Crohn's disease	0.000292	0.000602	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—UBE2D1—Crohn's disease	0.000284	0.000586	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—UBE2D1—Crohn's disease	0.000284	0.000586	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RASGRP1—Crohn's disease	0.000282	0.000582	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.00028	0.000578	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RIPK2—Crohn's disease	0.000275	0.000568	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RIPK2—Crohn's disease	0.000275	0.000568	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL3—Crohn's disease	0.000268	0.000554	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL3—Crohn's disease	0.000268	0.000554	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.000262	0.000541	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RASGRP1—Crohn's disease	0.00026	0.000536	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RASGRP1—Crohn's disease	0.00026	0.000536	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TYK2—Crohn's disease	0.000258	0.000533	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—JAK2—Crohn's disease	0.000256	0.000528	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SOCS1—Crohn's disease	0.000255	0.000527	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—JAK2—Crohn's disease	0.000246	0.000509	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—TYK2—Crohn's disease	0.000244	0.000503	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—JAK2—Crohn's disease	0.000236	0.000486	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—JAK2—Crohn's disease	0.000236	0.000486	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SOCS1—Crohn's disease	0.000235	0.000485	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SOCS1—Crohn's disease	0.000235	0.000485	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CD4—Crohn's disease	0.000234	0.000482	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CXCL8—Crohn's disease	0.000234	0.000482	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—JAK2—Crohn's disease	0.000232	0.00048	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTGS2—Crohn's disease	0.000232	0.000479	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—TYK2—Crohn's disease	0.000224	0.000463	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—TYK2—Crohn's disease	0.000224	0.000463	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ALB—Crohn's disease	0.000222	0.000458	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SMAD3—Crohn's disease	0.000221	0.000455	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CXCL8—Crohn's disease	0.000215	0.000444	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CXCL8—Crohn's disease	0.000215	0.000444	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—JAK2—Crohn's disease	0.000214	0.000441	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—JAK2—Crohn's disease	0.000214	0.000441	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CXCL8—Crohn's disease	0.000212	0.000438	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL2RA—Crohn's disease	0.000204	0.000422	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SMAD3—Crohn's disease	0.000203	0.000419	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SMAD3—Crohn's disease	0.000203	0.000419	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CXCL8—Crohn's disease	0.000195	0.000403	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCL8—Crohn's disease	0.000195	0.000403	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS2—Crohn's disease	0.000194	0.000401	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLA2G4F—Crohn's disease	0.000188	0.000388	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL2RA—Crohn's disease	0.000188	0.000388	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL2RA—Crohn's disease	0.000188	0.000388	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—STAT3—Crohn's disease	0.000181	0.000373	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTMR3—Crohn's disease	0.00016	0.00033	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TYK2—Crohn's disease	0.000144	0.000297	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—JAK2—Crohn's disease	0.000137	0.000283	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TYK2—Crohn's disease	0.000132	0.000273	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TYK2—Crohn's disease	0.000132	0.000273	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6—Crohn's disease	0.000126	0.000261	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—JAK2—Crohn's disease	0.000126	0.000261	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—JAK2—Crohn's disease	0.000126	0.000261	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL8—Crohn's disease	0.000125	0.000259	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—FADS1—Crohn's disease	0.000125	0.000257	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6—Crohn's disease	0.000119	0.000246	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPX4—Crohn's disease	0.000117	0.000241	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL8—Crohn's disease	0.000115	0.000238	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL8—Crohn's disease	0.000115	0.000238	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GCKR—Crohn's disease	0.000113	0.000233	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6—Crohn's disease	0.00011	0.000226	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6—Crohn's disease	0.00011	0.000226	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STAT3—Crohn's disease	0.000101	0.000208	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STAT3—Crohn's disease	9.27e-05	0.000191	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STAT3—Crohn's disease	9.27e-05	0.000191	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	8.06e-05	0.000166	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	7.05e-05	0.000145	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6—Crohn's disease	7.04e-05	0.000145	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6—Crohn's disease	6.48e-05	0.000134	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6—Crohn's disease	6.48e-05	0.000134	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALB—Crohn's disease	3.59e-05	7.41e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—Crohn's disease	3.14e-05	6.48e-05	CbGpPWpGaD
